{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:06:02Z","timestamp":1781625962674,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research to Prevent Blindness Unrestricted Grant","award":["GR004596-1"],"award-info":[{"award-number":["GR004596-1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Intravitreal injections are standard treatment for various manifestations of age-related macular degeneration (AMD) but are associated with rare complications, including central retinal vein occlusion (CRVO). This report describes three cases of CRVO following intravitreal injections in patients with AMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective case series describing three patients with AMD who developed CRVO after intravitreal injections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CRVO occurred after ranibizumab (Lucentis, South San Francisco, CA), brolucizumab (Beovu, Novartis, Basel, Switzerland), and pegcetacoplan (Syfovre, Apellis, Waltham, MA) injections. All patients had multiple systemic vasculopathic risk factors. No intraocular inflammation or vasculitis was observed on examination, and fluorescein angiography was not performed. Visual outcomes were poor despite anti-VEGF treatment. None of the three patients developed neovascular glaucoma under our observation. The timing relationship between injection and CRVO varied, and causality could not be established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CRVO may occur after intravitreal injections across different drug classes, even with agents that have low inflammatory potential. These cases highlight the multifactorial nature of this event and the importance of considering systemic vasculopathy when evaluating post-injection complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00781-3","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:05:25Z","timestamp":1765821925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Central retinal vein occlusion following intravitreal injections: a case series highlighting multifactorial risk"],"prefix":"10.1186","volume":"12","author":[{"given":"Michael","family":"Antonietti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Smiddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1441-9473","authenticated-orcid":false,"given":"Stephen G.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"29\u201330","key":"781_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3238\/arztebl.2020.0513","volume":"20","author":"A Stahl","year":"2020","unstructured":"Stahl A. The diagnosis and treatment of Age-Related macular degeneration. Dtsch Arztebl Int Jul. 2020;20(29\u201330):513\u201320. https:\/\/doi.org\/10.3238\/arztebl.2020.0513.","journal-title":"Dtsch Arztebl Int Jul"},{"issue":"3","key":"781_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/icu.0000000000000850","volume":"1","author":"D Patel","year":"2022","unstructured":"Patel D, Patel SN, Chaudhary V, Garg SJ. Complications of intravitreal injections: 2022. Curr Opin Ophthalmol May. 2022;1(3):137\u201346. https:\/\/doi.org\/10.1097\/icu.0000000000000850.","journal-title":"Curr Opin Ophthalmol May"},{"key":"781_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/opth.S29075","volume":"6","author":"AM Mansour","year":"2012","unstructured":"Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG. Insight into 144 patients with ocular vascular events during VEGF antagonist injections. Clin Ophthalmol. 2012;6:343\u201363. https:\/\/doi.org\/10.2147\/opth.S29075.","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"781_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/APO.0000000000000598","volume":"01","author":"F Romano","year":"2023","unstructured":"Romano F, Lamanna F, Gabrielle PH, et al. Update on retinal vein occlusion. Asia Pac J Ophthalmol (Phila) Mar-Apr. 2023;01(2):196\u2013210. https:\/\/doi.org\/10.1097\/APO.0000000000000598.","journal-title":"Asia Pac J Ophthalmol (Phila) Mar-Apr"},{"key":"781_CR5","doi-asserted-by":"publisher","unstructured":"Jabbehdari S, Yazdanpanah G, Cantor LB, Hajrasouliha AR. A narrative review on the association of high intraocular pressure and glaucoma in patients with retinal vein occlusion. Ann Transl Med. Oct 2022;10(19):1072. https:\/\/doi.org\/10.21037\/atm-22-2730.","DOI":"10.21037\/atm-22-2730"},{"issue":"9","key":"781_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14779072.2022.2112667","volume":"20","author":"M Orskov","year":"2022","unstructured":"Orskov M, Vorum H, Bjerregaard Larsen T, et al. A review of risk factors for retinal vein occlusions. Expert Rev Cardiovasc Ther Sep. 2022;20(9):761\u201372. https:\/\/doi.org\/10.1080\/14779072.2022.2112667.","journal-title":"Expert Rev Cardiovasc Ther Sep"},{"issue":"4","key":"781_CR7","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1111\/aos.14608","volume":"99","author":"YN Kim","year":"2021","unstructured":"Kim YN, Shin JW, Park YJ, et al. Glaucoma as a prognostic factor of central retinal vein occlusion: visual and anatomical outcomes and occurrence of ischaemic central retinal vein occlusion. Acta Ophthalmol Jun. 2021;99(4):e523\u201330. https:\/\/doi.org\/10.1111\/aos.14608.","journal-title":"Acta Ophthalmol Jun"},{"issue":"6","key":"781_CR8","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.ajo.2008.07.007","volume":"146","author":"JE Kim","year":"2008","unstructured":"Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol Dec. 2008;146(6):930\u2013e41. https:\/\/doi.org\/10.1016\/j.ajo.2008.07.007.","journal-title":"Am J Ophthalmol Dec"},{"issue":"2","key":"781_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ajo.2014.04.029","volume":"158","author":"NA Yannuzzi","year":"2014","unstructured":"Yannuzzi NA, Patel SN, Bhavsar KV, Sugiguchi F, Freund KB. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol Aug. 2014;158(2):319\u2013e3272. https:\/\/doi.org\/10.1016\/j.ajo.2014.04.029.","journal-title":"Am J Ophthalmol Aug"},{"issue":"12","key":"781_CR10","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/ijg.0000000000001894","volume":"1","author":"AM Levin","year":"2021","unstructured":"Levin AM, Chaya CJ, Kahook MY, Wirostko BM. Intraocular pressure elevation following intravitreal Anti-VEGF injections: Short- and Long-term considerations. J Glaucoma Dec. 2021;1(12):1019\u201326. https:\/\/doi.org\/10.1097\/ijg.0000000000001894.","journal-title":"J Glaucoma Dec"},{"issue":"6","key":"781_CR11","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.ajo.2007.03.007","volume":"143","author":"S Peters","year":"2007","unstructured":"Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol Jun. 2007;143(6):995\u20131002. https:\/\/doi.org\/10.1016\/j.ajo.2007.03.007.","journal-title":"Am J Ophthalmol Jun"},{"issue":"14","key":"781_CR12","first-page":"5271","volume":"52","author":"U Schraermeyer","year":"2011","unstructured":"Schraermeyer U, Schultheiss S, Hofmeister S, Julien S. Bevacizumab immune complexes activate platelets and cause thrombosis in choroidal vessels of primate eyes. Investig Ophthalmol Vis Sci. 2011;52(14):5271\u20135271.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"6","key":"781_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1755-3768.2009.01526.x","volume":"88","author":"P Bonnin","year":"2010","unstructured":"Bonnin P, Pournaras JA, Lazrak Z, et al. Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin(\u00ae)) in neovascular age-related macular degeneration. Acta Ophthalmol Sep. 2010;88(6):641\u20135. https:\/\/doi.org\/10.1111\/j.1755-3768.2009.01526.x.","journal-title":"Acta Ophthalmol Sep"},{"issue":"5","key":"781_CR14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/iae.0b013e3181d2f145","volume":"30","author":"M Michaelides","year":"2010","unstructured":"Michaelides M, Fraser-Bell S, Hamilton R, et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): report 1. Retina May. 2010;30(5):781\u20136. https:\/\/doi.org\/10.1097\/iae.0b013e3181d2f145.","journal-title":"Retina May"},{"issue":"6","key":"781_CR15","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1167\/iovs.10-5842","volume":"52","author":"S Sacu","year":"2011","unstructured":"Sacu S, Pemp B, Weigert G, et al. Response of retinal vessels and retrobulbar hemodynamics to intravitreal Anti-VEGF treatment in eyes with branch retinal vein occlusion. Investig Ophthalmol Vis Sci. 2011;52(6):3046\u201350. https:\/\/doi.org\/10.1167\/iovs.10-5842.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"10","key":"781_CR16","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1097\/iae.0000000000003862","volume":"1","author":"P Pakravan","year":"2023","unstructured":"Pakravan P, Patel V, Lai J, INTRAOCULAR INFLAMMATION INCIDENCE AFTER INTRAVITREAL BROLUCIZUMAB INJECTION FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION, et al. Retina Oct. 2023;1(10):1717\u201322. https:\/\/doi.org\/10.1097\/iae.0000000000003862.","journal-title":"Retina Oct"},{"issue":"4","key":"781_CR17","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","volume":"128","author":"GJ Jaffe","year":"2021","unstructured":"Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor Avacincaptad Pegol for geographic atrophy due to Age-Related macular degeneration: A randomized pivotal phase 2\/3 trial. Ophthalmology Apr. 2021;128(4):576\u201386. https:\/\/doi.org\/10.1016\/j.ophtha.2020.08.027.","journal-title":"Ophthalmology Apr"},{"issue":"1","key":"781_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/24741264231220224","volume":"8","author":"AJ Witkin","year":"2024","unstructured":"Witkin AJ, Jaffe GJ, Srivastava SK, Davis JL, Kim JE. Retinal vasculitis after intravitreal pegcetacoplan: report from the ASRS research and safety in therapeutics (ReST) committee. J Vitreoretin Dis Jan-Feb. 2024;8(1):9\u201320. https:\/\/doi.org\/10.1177\/24741264231220224.","journal-title":"J Vitreoretin Dis Jan-Feb"},{"issue":"2","key":"781_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/24741264241228648","volume":"8","author":"M Abi Karam","year":"2024","unstructured":"Abi Karam M, Davis JL, Schwartz SG. Occlusive retinal vasculitis after a single injection of Pegcetacoplan. J Vitreoretin Dis Mar-Apr. 2024;8(2):205\u20139. https:\/\/doi.org\/10.1177\/24741264241228648.","journal-title":"J Vitreoretin Dis Mar-Apr"},{"key":"781_CR20","doi-asserted-by":"publisher","unstructured":"Nahar A, Eliott D, Avery RL, et al. Retinal vasculopathy and choroiditis after Pegcetacoplan injection: clinicopathologic support for a drug hypersensitivity reaction. Ophthalmol Retina Oct. 2024;16. https:\/\/doi.org\/10.1016\/j.oret.2024.10.005.","DOI":"10.1016\/j.oret.2024.10.005"},{"issue":"1","key":"781_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology Jan. 2009;116(1):57\u2013e655. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.018.","journal-title":"Ophthalmology Jan"},{"issue":"14","key":"781_CR22","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"5","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med Oct. 2006;5(14):1419\u201331. https:\/\/doi.org\/10.1056\/NEJMoa054481.","journal-title":"N Engl J Med Oct"},{"issue":"7","key":"781_CR23","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mon\u00e9s","year":"2021","unstructured":"Mon\u00e9s J, Srivastava SK, Jaffe GJ, et al. Risk of Inflammation, retinal Vasculitis, and retinal Occlusion-Related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology Jul. 2021;128(7):1050\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2020.11.011.","journal-title":"Ophthalmology Jul"},{"issue":"10411","key":"781_CR24","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/s0140-6736(23)01520-9","volume":"21","author":"JS Heier","year":"2023","unstructured":"Heier JS, Lad EM, Holz FG, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet Oct. 2023;21(10411):1434\u201348. https:\/\/doi.org\/10.1016\/s0140-6736(23)01520-9.","journal-title":"Lancet Oct"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00781-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00781-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00781-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:15:24Z","timestamp":1781622924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-025-00781-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["781"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00781-3","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report was conducted in accordance with the Declaration of Helsinki. The collection and evaluation of all protected health information was performed in a Health Insurance Portability and Accountability Act (HIPAA)\u2013compliant manner. Institutional Review Board approval was obtained from the University of Miami Miller School of Medicine Sciences Subcommittee for the Protection of Human Subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Consent was obtained prior to performing the procedure, including permission for publication of all photographs and images included herein.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}